Caveolin-1 expression during the progression of pulmonary hypertension

被引:27
作者
Huang, Jing [1 ]
Wolk, John H. [2 ]
Gewitz, Michael H. [1 ]
Mathew, Rajamma [1 ,3 ]
机构
[1] New York Med Coll, Pediat Cardiol Sect, Maria Fareri Childrens Hosp, Valhalla, NY 10595 USA
[2] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[3] New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA
关键词
caveolin-1; endothelial cells; pulmonary hypertension; smooth muscle cells; vWF; VASCULAR SMOOTH-MUSCLE; VON-WILLEBRAND-FACTOR; NITRIC-OXIDE; MATRIX METALLOPROTEINASES; PROLIFERATION; CELLS; MIGRATION; GROWTH; DYSFUNCTION; INHIBITOR;
D O I
10.1258/ebm.2012.011382
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Caveolin-1 plays a pivotal role in maintaining vascular health. Progressive loss of endothelial caveolin-1 and activation of proliferative and anti-apoptotic pathways occur before the onset of monocrotaline (MCT)-induced pulmonary hypertension (PH), and the rescue of endothelial caveolin-1 attenuates PH. Recently, we reported endothelial caveolin-1 loss associated with enhanced expression of caveolin-1 in smooth muscle cells (SMC) with subsequent neointima formation in human PH. To examine whether the loss of endothelial caveolin-1 followed by an enhanced expression in SMC is a sequential event in the progression of PH, we studied rats at two and four weeks post-MCT. Right ventricular (RV) systolic pressure, RV hypertrophy, pulmonary vascular histology, and the expression of caveolin-1 and endothelial membrane proteins (platelet/endothelial cell adhesion molecule-1 [PECAM-1], both alpha and beta subunits of soluble guanylate cyclase [sGC]), von Willebrand factor (vWF), smooth muscle a-actin, proliferative and anti-apoptotic factors (PY-STAT3 and Bcl-xL) and matrix metalloproteinase (MMP) 2 in the lungs were examined. PH was accompanied by a progressive loss of endothelial caveolin-1, activation of PY-STAT3, increased Bcl-xL expression and vascular remodeling at two and four weeks post-MCT. Loss of PECAM-1 and sGC (both subunits) paralleled that of caveolin-1, whereas vWF was well preserved at two weeks post-MCT. At four weeks post-MCT, 29% of the arteries showed a loss of vWF in addition to endothelial caveolin-1, and 70% of these arteries exhibited enhanced expression of caveolin-1 in SMC; and there was increased expression and activity of MMP2. In conclusion, MCT-induced endothelial injury disrupts endothelial cell membrane with a progressive loss of endothelial caveolin-1, and the activation of proliferative and antiapoptotic pathways leading to PH. Subsequent extensive endothelial cell damage results in enhanced expression of caveolin-1 in SMC. In addition, there is a progressive increase in MMP2 expression and activity. These alterations may further facilitate cell proliferation, matrix degradation and cell migration, thus contributing to the progression of the disease.
引用
收藏
页码:956 / 965
页数:10
相关论文
共 46 条
[1]   Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains [J].
Annabi, B ;
Lachambre, MP ;
Bousquet-Gagnon, N ;
Pagé, M ;
Gingras, D ;
Béliveau, R .
BIOCHEMICAL JOURNAL, 2001, 353 :547-553
[2]   Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry [J].
Badesch, David B. ;
Raskob, Gary E. ;
Elliott, C. Greg ;
Krichman, Abby M. ;
Farber, Harrison W. ;
Frost, Adaani E. ;
Barst, Robyn. J. ;
Benza, Raymond L. ;
Liou, Theodore G. ;
Turner, Michelle ;
Giles, Scott ;
Feldkircher, Kathy ;
Miller, Dave P. ;
McGoon, Michael D. .
CHEST, 2010, 137 (02) :376-387
[3]   Caveolin-1 Upregulation Mediates Suppression of Primary Breast Tumor Growth and Brain Metastases by Stat3 Inhibition [J].
Chiu, Wen-Tai ;
Lee, Hsueh-Te ;
Huang, Feng-Ju ;
Aldape, Kenneth D. ;
Yao, Jun ;
Steeg, Patricia S. ;
Chou, Cheng-Yang ;
Lu, Zhimin ;
Xie, Keping ;
Huang, Suyun .
CANCER RESEARCH, 2011, 71 (14) :4932-4943
[4]   Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart [J].
Chow, A. K. ;
Cena, J. ;
El-Yazbi, A. F. ;
Crawford, B. D. ;
Holt, A. ;
Cho, W. J. ;
Daniel, E. E. ;
Schulz, R. .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2007, 42 (04) :896-901
[5]   Characterization of von Willebrand factor in primary pulmonary hypertension [J].
Collados, MT ;
Sandoval, J ;
López, S ;
Massó, FA ;
Páez, A ;
Borbolla, JR ;
Montaño, LF .
HEART AND VESSELS, 1999, 14 (05) :246-252
[6]   Identification of peptide and protein ligands for the caveolin-scaffolding domain - Implications for the interaction of caveolin with caveolae-associated proteins [J].
Couet, J ;
Li, SW ;
Okamoto, T ;
Ikezu, T ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (10) :6525-6533
[7]   Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :21-34
[8]   Binding of 92 kDa and 72 kDa progelatinases to insoluble elastin modulates their proteolytic activation [J].
Emonard, H ;
Hornebeck, W .
BIOLOGICAL CHEMISTRY, 1997, 378 (3-4) :265-271
[9]   COMPOSITION OF THE VONWILLEBRAND-FACTOR STORAGE ORGANELLE (WEIBEL-PALADE BODY) ISOLATED FROM CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS [J].
EWENSTEIN, BM ;
WARHOL, MJ ;
HANDIN, RI ;
POBER, JS .
JOURNAL OF CELL BIOLOGY, 1987, 104 (05) :1423-1433
[10]   Caveolin, caveolae, and endothelial cell function [J].
Frank, PG ;
Woodman, SE ;
Park, DS ;
Lisanti, MP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (07) :1161-1168